ARTICLE | Clinical News

Duvelisib: Completed Phase II enrollment

October 5, 2015 7:00 AM UTC

Infinity completed enrollment of 120 patients who are refractory to Rituxan rituximab and to chemotherapy or radioimmunotherapy in the open-label, international Phase II DYNAMO trial evaluating 25 mg oral duvelisib twice daily in 28-day cycles for up to 13 cycles. Patients may continue treatment for an additional year if they show evidence of a complete or partial response. ...